Aeolus Pharmaceuticals awarded $4.3 million grant to combat nerve agents
The grant was awarded to Manisha Patel of the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences to test the efficacy of AEOL 10150 against soman and other dangerous nerve agents. Patel led the research pilot study of AEOL 10150, which showed neuroprotection, a decrease in oxidative stress and an increased rate of survival among rats exposed to pilocarpine, a host for soman and sarin gas.
"Injection of AEOL10150 60 minutes after pilocarpine in the presence of standard therapy resulted in improved survival and near complete inhibition of oxidative stress indices in the hippocampus," Patel said.
The current treatment for nerve agent exposure is benzodiazepines and Atropine; researchers hope to add AEOL 10150 to the list. The results of the pilot study were announced at the 6th Annual CounterACT Countermeasures Against Chemical Threats Network Research Symposium in Washington, D.C.; the presentation was included as part of Patel's grant application.
"Recent events demonstrate the danger of chemical weapons, and highlight the importance of both the NIH CounterACT and Biomedical Advanced Research and Development Authority programs' funding to develop and acquire treatments for chemical radiological, and biological threats," Aeolus Pharmaceuticals President and CEO John L. McManus said. "AEOL 10150 continues to demonstrate its efficacy against a broad-spectrum of chemical and radiological threats, which increases its utility as a countermeasure to protect citizens and soldiers from these threats."